The U.S. Food and Drug Administration (FDA) on Wednesday authorized a novel anti-obesity medication named Foundayo. Administered once daily, this tablet is produced by the pharmaceutical firm Eli Lilly, which also manufactures the popular weight-loss injection, Zepbound.
Foundayo belongs to a class of medication identified as a GLP-1 agent, a group encompassing competing products like Ozempic and Wegovy. These pharmaceuticals emulate an endogenous hormone in the body that manages glycemic levels, retards digestive processes, and communicates a sense of repletion to the brain.
This marks the second GLP-1 tablet for shedding pounds available commercially. In December, Novo Nordisk obtained FDA authorization for its oral formulation of Wegovy. The company’s initial iteration of Wegovy is an injection administered once a week. While the Wegovy pill necessitates ingestion on an unburdened stomach early in the day, Lilly states that Foundayo may be consumed at any hour without dietary or hydration limits.
Given the significant demand for injectable GLP-1 drugs, pharmaceutical firms are rushing to develop oral slimming agents, which could prove more appealing to certain individuals and possibly broaden the market for GLP-1s. Tablets are also simpler to produce than injectable medications, which could aid in ensuring uninterrupted availability for patients. GLP-1 pharmaceuticals experienced an acute scarcity from late 2022 through early 2025 because requisition surpassed production capability.
“Aside from provision and economic feasibility, one of the more substantial impediments to uptake has been that some patients are simply unwilling to receive a shot,” states Ken Custer, executive vice president of Eli Lilly. “That might be due to the needle itself, but it could also signify to them that their condition implies a graver state of their health than they perceive it to be currently. For individuals seeking to commence their path to weight control, perhaps a tablet presents a more accessible starting point.”
Similar to GLP-1 injectables, Foundayo commences with a minimal dosage and is progressively augmented to mitigate queasiness, emesis, and loose stools that may accompany these medications.
During a clinical study, participants receiving the maximum dosage of Foundayo over an 18-month period shed an average of 27 pounds, or 12.4 percent of their total body mass. Subjects receiving an inert substance, conversely, only shed 2 pounds, or less than 1 percent of their body weight, within the identical period. Lilly’s tirzepatide, the primary component in its injectables Mounjaro and Zepbound, has demonstrated a greater than 20 percent decrease in body mass.
Regarding Novo Nordisk’s Wegovy tablet, research subjects attained a mean reduction in body mass of 13.6 percent after 16 months. There have been no direct comparative studies assessing the effectiveness of Foundayo versus the Wegovy pill.
Eli Lilly conducted research to ascertain the outcomes when individuals transition from an injectable GLP-1 drug to Foundayo and discovered that it assisted them in preserving the majority of their lost weight. Those who transitioned to the tablet from injectable Wegovy experienced an average differential regain of 2 pounds, while those who switched to Foundayo from Zepbound accumulated an average of 11 pounds. Orforglipron, the primary component in Foundayo, is also under investigation as a prospective therapy for type 2 diabetes, sleep apnea characterized by obstruction, knee discomfort from osteoarthritis, and various other ailments.
Foundayo can now be accessed through the consumer-direct platform LillyDirect, with dispatch commencing April 6. Eli Lilly states Foundayo is slated for broader accessibility via American brick-and-mortar pharmacies and virtual healthcare platforms soon thereafter. The tablet was incorporated into a November 2025 accord for provision through the TrumpRx platform.
In its declaration on Wednesday, the FDA stated it assessed Foundayo in merely 50 days as an element of a novel trial initiative designed to accelerate authorizations for medications congruent with national public health objectives. New drug sanctions customarily require six to 10 months.
{content}
Source: {feed_title}